News and Events
- HemaFlo Therapeutics Announces Issuance of Key Patent for NephroFlow
Broad claims cover use of NephroFlow to treat Acute Kidney Injury
Carlsbad, CA, February 8, 2016 — HemaFlo Therapeutics, Inc. announced today the United States Patent and Trademark Office (USPTO) has issued US Patent Number 9,119,880 covering the use of NephroFlow to treat acute kidney injury (AKI).
Dale Peterson, PhD, HemaFlo’s founder, said, “We are pleased to secure our rights to such a powerful technology.”
NephroFlow is a proprietary product that contains a Drag Reducing Polymer (DRP) with the potential to improve vascular perfusion and reduce the complications associated with AKI. In a rat model of ischemic AKI, NephroFlow demonstrated a statistically significant improvement in kidney function.
The initial indication for NephroFlow will be in post-surgical patients who have early stage AKI. Treatment with NephroFlow is intended to increase perfusion to the kidney and reduce the complications, morbidities and mortalities associated with prolonged and advanced-stage AKI. In the longer term, NephroFlow
- Michael Martino Named President and Chief Executive Officer of HemaFlo Therapeutics
Industry veteran brings operating expertise to development-stage company focused on delivering therapies for diseases caused by poor blood flow
Carlsbad, CA, January 18, 2016 — HemaFlo Therapeutics, Inc. announced today the appointment of Michael A. Martino as President, Chief Executive Officer and a member of the Board of Directors. Mr. Martino was most recently President and Chief Executive Officer of Ambit Biosciences until its acquisition by Daiichi Sankyo.
Dale Peterson, PhD, HemaFlo’s founder, said, “We are pleased to attract a seasoned executive with expertise in building and leading teams, developing innovative strategies that create value, executing deals and raising capital in the private and public sectors. Michael’s experience is vital to HemaFlo as we take the next steps to accelerate the development of NephroFlow, our lead product for the treatment of acute kidney injury.”
“I am pleased to collaborate with a talented entrepreneur like Dale who has successfully commercialized more than
- DRP Biomedical Is Now HemaFlo Therapeutics
Change highlights company mission to develop therapies for diseases characterized by poor blood flow
Carlsbad, CA, January 18, 2016 — DRP Biomedical, Inc., announced today that it has changed its corporate name to HemaFlo Therapeutics, Inc., to highlight the company’s mission to develop therapies for diseases characterized by poor blood flow or ischemia.
“DRP is an acronym for our core Drag Reducing Polymer technology,” said Michael A. Martino, HemaFlo’s President and Chief Executive Officer.
“We believe this technology has broad applicability in a number of acute and chronic disease states that are associated with decreased tissue perfusion due to reduced blood flow. The HemaFlo Therapeutics name more completely reflects our broader mission to develop therapies for these diseases, and DRP will continue to be used to describe our technology.”
The initial application of HemaFlo’s DRP technology is reflected in NephroFlow, the company’s lead product in preclinical development to treat acute kidney injury (AKI),
- Breakthrough Medical Device Clears FDA Hurdle
For Immediate Release: September 29, 2014
Contact: Dale Peterson, PhD, founder DRP Biomedical, (760) 607-6460, DRPBiomed@gmail.com
Breakthrough Medical Device Clears FDA Hurdle
NephroFlow® Designed to Help Millions Stricken with Loss of Kidney Function
CARLSBAD, CA-Today DRP Biomedical Inc. is applauding a U.S. Food and Drug Administration (FDA) decision to regulate its breakthrough technology to treat acute kidney injury as a medical device rather than as a drug.
“This is a very important FDA determination because it will further streamline the final development and testing of NephroFlow, a medical device designed to prevent permanent kidney damage or death for four million patients in the United States each year,” said Dale Peterson, Ph.D., the inventor and founder of DRP Biomedical.
Acute kidney injury (AKI) is a sudden loss of kidney function which has severe short and long term consequences. It is a relatively common clinical condition that results in death for a large number of